

Frank Jessen

Personal Data

Title	Prof. Dr.
First name	Jessen
Name	Frank
Current position	Full Professor of Medicine, permanent Director, Dep. of Psychiatry and Psychotherapy, University Hospital Cologne
Current institution(s)/site(s), country	Dep. of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne, Germany
Identifiers/ORCID	0000-0003-1067-2102

Qualifications and Career

Stages	Periods and Details
Medical Doctoral Degree	1998, PD. Dr. G. Heinz, University of Saarland, Homburg, Germany
Medical School	1988–1995, University of Saarland, Homburg, Germany

Stages of Academic/Professional Career

Visiting Professor	2023, 2024, Keio University, Tokyo, Japan
Full Professor (W3)	2015–present, University of Cologne, Germany
Director	2015–present, Dep. of Psychiatry and Psychotherapy, University Hospital Cologne, Germany
Group Leader	2010–present, Clinical Alzheimer Research, German Centre for Neurodegenerative Diseases (DZNE) Bonn/Cologne, Germany
Associate Professor (W2)	2010–2014, Clinical Dementia Research, University of Bonn, Vice Director, Department of Psychiatry, University Hospital Bonn, Germany
Attending Physician	2002–2010, Head of the Alzheimer Research Group, Head of Memory Clinic, Department of Psychiatry, University Hospital Bonn, Germany
Venia Legendi for Psychiatry and Psychotherapy	2004, University of Saarland, Homburg, Germany
Board Examination	2002, Psychiatry and Psychotherapy
Research Fellowship	1998–1999, American Alzheimer Association, University of Bonn, Germany
Resident	1996–2002, Psychiatry and Neurology, University Hospital Bonn, Germany
Resident	1995–1996, Neuropathology, University Hospital Düsseldorf, Germany

Activities in the Research System

Institutional Responsibilities (selected)

- 2024–present Clinical Executive Board Member, German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany
- 2015–present Founder and Chair, Interdisciplinary Memory Clinic, The Alzheimer Prevention Centre and the Late Life Depression Outpatient Clinic, University Hospital Cologne, Germany
- 2012–2024 Clinical Board Member, German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany

Service to the Scientific Community (selected)

- 2024–present Member, DFG Fachkollegium “Neuroscience”, Bonn, Germany
- 2023, 2016, 2008 Coordinator and Main Author, National Guideline on the Diagnosis and Treatment of Dementia (AWMF S3-guideline)
- 2022–present SAB Member, Alzheimer Europe
- 2020–present Founder and past Chair, German Memory Clinic Network (DNG)
- 2020–2022 Program Committee Member and Symptomatic Manifestation Working Group Chair, Alzheimer’s Association International Conference (AAIC)
- 2019–present Executive Board Member, German Psychiatric Society (DGPPN), responsible for dementia-related topics and guideline program
- 2018–present SAB Member, German Alzheimer Association (DAIzG)
- 2018–2023 Associated Editor, Alzheimer Research and Therapy
- 2016–2018 Member, NIA-AA Working Group for the Research Criteria of Alzheimer’s Disease, NIH, USA
- 2015–2017 SAB Member, International Society to Advance Alzheimer’s Research and Treatment (ISTAART)
- 2014 Scientific Advisor, European Medicines Agency (EMA)
- 2013–present Executive Board Member and current Chair, European Alzheimer’s Disease Consortium (EACD)
- 2013–2017 Founder and Chair, Subjective Cognitive Decline Initiative (SCD-I) and the ISTAART SCD Professional Interest Area
- 2010 Scientific Advisor, European Medicines Agency (EMA)

Scientific Results

Category A

Dafsari, F.S., Bewernick, B., Böhringer, S., Domschke, K., Elsaesser, M., Löbner, M., Lupp, M., Schmitt, S., Wingenfeld, K., Wolf, E., Zehender, N., Hellmich, M., Müller, W., Wagner, M., Peters, O., Frölich, L., Riedel-Heller, S., Schramm, E., Hautzinger, M., and **Jessen, F.** (2024). Perceived physical health and cognitive behavioral therapy vs supportive psychotherapy outcomes in adults with late-life depression: A secondary analysis of a randomized clinical trial. **JAMA Netw Open** 7:e245841. doi: 10.1001/jamanetworkopen.2024.5841. (open access)

Dafsari, F.S., Bewernick, B., Böhringer, S., Domschke, K., Elsaesser, M., Löbner, M., Lupp, M., Preis, L., Püsken, J., Schmitt, S., Szekely, A.J., Hellmich, M., Müller, W., Wagner, M., Peters, O., Frölich, L., Riedel-Heller, S., Schramm, E., Hautzinger, M., and **Jessen, F.** (2023). Cognitive behavioral therapy for late-life depression (CBTlate): Results of a multicenter, randomized, observer-blinded, controlled trial. **Psychother Psychosom** 92:180–192. doi: 10.1159/000529445. (open access)

Jessen, F., Wolfsgruber, S., Kleineindam, L., Spottke, A., Altenstein, S., Bartels, C., Berger, M., Brosseron, F., Daamen, M., Dichgans, M., Dobisch, L., Ewers, M., Fenski, F., Fliessbach, K., Freiesleben, S.D., Glanz, W., Görß, D., Gürsel, S., Janowitz, D., Kilimann, I., Kobeleva, X., Lohse, A., Maier, F., Metzger, C., Munk, M., Preis, L., Sanzenbacher, C., Spruth, E., Rauchmann, B., Vukovich, R., Yakupov, R., Weyrauch, A.S., Ziegler, G., Schmid, M., Laske, C., Pernecky, R., Schneider, A., Wiltfang, J., Teipel, S., Bürger, K., Priller, J., Peters, O., Ramirez, A., Boecker, H., Heneka, M.T., Wagner, M., and Düzel, E. (2023). Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. **Alzheimers Dement** 19:487–497. doi: 10.1002/alz.12674. (open access)

Kruse, C., Maier, F., Spottke, A., Bach, J.-P., Bartels, C., Buerger, K., Fellgiebel, A., Fliessbach, K., Frölich, L., Hausner, L., Hellmich, M., Kloppel, S., Klostermann, A., Kornhuber, J., Laske, C., Peters, O., Priller, J., Richter-Schmidinger, T.; Schneider, A., Shah-Hosseini, K., Teipel, S., von Arnim, C.A.F., Wiltfang, J., van der Wurp, H., Dodel, R., and **Jessen, F.** (2023). Apathy in patients with Alzheimer’s disease is a cost-driving factor. **Alzheimers Dement** 19:2853–2864. doi: 10.1002/alz.12915. (open access)

Wunderlich, G., Blahova, Z., Garcia, M., and **Jessen, F.** (2023). Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial. **Alzheimers Res Ther** 15:24. doi: 10.1186/s13195-023-01163-3. (open access)

Düzel, E., Ziegler, G., Berron, D., Maass, A., Schütze, H., Cardenas-Blanco, A., Glanz, W., Metzger, C., Dobisch, L., Reuter, M., Spottke, A., Brosseron, F., Fliessbach, K., Heneka, M.T., Laske, C., Peters, O., Priller, J., Spruth, E.J., Ramirez, A., Speck, O., Schneider, A., Teipel, S., Kilimann, I., Jens, W., Schott, B.H., Preis, L., Gref, D., Maier, F., Munk, M.H., Roy, N., Ballarini, T., Yakupov, R., Haynes, J.D., Dechent, P., Scheffler, K., Wagner, M., and **Jessen, F.** (2022). Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction. **Brain** 145:1473–1485. doi: 10.1093/brain/awab405. (open access)

Rostamzadeh, A., Kahlert, A., Kalthegener, F., and **Jessen, F.** (2022). Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review. **Alzheimers Res Ther** 14:18. doi: 10.1186/s13195-021-00956-8. (open access)

Rostamzadeh, A., Bohr, L., Wagner, M., Baethge, C., and **Jessen, F.** (2022). Progression of subjective cognitive decline to MCI or dementia in relation to biomarkers for Alzheimer disease: A Meta-analysis. **Neurology** 99:e1866–e1874. doi: 10.1212/WNL.0000000000201072. (open access)

Jessen, F., Amariglio, R.E., Buckley, R.F., van der Flier, W.M., Han, Y., Molinuevo, J.L., Rabin, L., Rentz, D.M., Rodriguez-Gomez, O., Saykin, A.J., Sikkes, S.A.M., Smart, C.M., Wolfsgruber, S., and Wagner, M. (2020). The characterisation of subjective cognitive decline. **Lancet Neurol** 19:271–278. doi: 10.1016/S1474-4422(19)30368-0. (open access)

Maier, F., Spottke, A., Bach, J.-P., Bartels, C., Buerger, K., Dodel, R., Fellgiebel, A., Fliessbach, K., Frölich, L., Hausner, L., Hellmich, M., Kloppel, S., Klostermann, A., Kornhuber, J., Laske, C., Peters, O., Priller, J., Richter-Schmidinger, T., Schneider, A., Shah-Hosseini, K., von Arnim, C.A.F., Wiltfang, J., and **Jessen, F.** (2020). Bupropion for the treatment of apathy in Alzheimer disease: A randomized clinical trial. **JAMA Netw Open** 3:e206027. doi: 10.1001/jamanetworkopen.2020.6027. (open access)

* *shared first authorship*, # *shared corresponding authorship*

Category B

Public Outreach Activities (selected)

2023	Stern, “Demenz vorbeugen: ”Was wichtig ist um geistig fit zu bleiben”
2023	Podcast “Geschichten aus der Psychiatrie”: #31 “Ein Chefarzt erzählt aus seinem Klinikalltag”
2022	Wissenspodcast DZNE “Hirn&Heinrich”: #30 “Lecanemab - Warum der neue Antikörper als Sensation gegen Alzheimer gefeiert wird”
2022	NDR Podcast: #68 “Demenz: Der Kampf um die graue Substanz”
2018	FAZ, “Eine frühe Diagnose bringt Vorteile”

Academic Distinctions

2022 Mack Award for the Study Group “Psychotherapy for age-related depression”, Elisabeth Mack-Usselmann & Dr. Michael Mack Foundation, First ever prize